by Paul | 10th February 2026 | News
Dr. Mantelli, former Chief Medical Officer at Dompé, spearheaded the successful clinical development program and FDA approval of Oxervate®, a blockbuster orphan therapy in corneal disease Dr. Mantelli will lead the clinical and regulatory strategy to advance the...
by Paul | 30th January 2026 | News
London and New York, NY, January 30, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announces that...
by Paul | 28th January 2026 | News
FDA confirms Phase 2b/3 clinical design, including primary endpoint, sample size, and development approach London and New York, NY, January 28, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies...
by Paul | 23rd January 2026 | News
London and New York, NY, January 23, 2026. OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and for inflammatory eye diseases, today announced that...
by Paul | 5th January 2026 | News
Accomplished industry leader Robert J. Dempsey brings extensive commercialization and ophthalmic expertise Gary S. Jacob, Ph.D., will transition to Chief Development Officer and continue to serve on the Board London and New York, NY, January 5, 2026. OKYO Pharma...
